Mitogen-activated protein kinase kinase
<templatestyles src="Module:Hatnote/styles.css"></templatestyles>
| Mitogen-activated protein kinase kinase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC number | 2.7.12.2 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
|
|||||||||
Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).
MAP2K is classified as EC 2.7.12.2.
There are seven genes:
- MAP2K1 (aka MEK1)
- MAP2K2 (aka MEK2)
- MAP2K3 (aka MKK3)
- MAP2K4 (aka MKK4)
- MAP2K5 (aka MKK5)
- MAP2K6 (aka MKK6)
- MAP2K7 (aka MKK7)
The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.[1] The acronym MEK derives from Mitogen/Extracellular signal-regulated Kinase.
Role in Melanoma
MEK is a member of the MAPK signaling cascade that is activated in melanoma.[2] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.
See also
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Falchook, Gerald S, Karl D Lewis, Jeffrey R Infante, Michael S Gordon, Nicholas J Vogelzang, Douglas J DeMarini, and Leslie A Fecher, et al. 2012. "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial." The Lancet Oncology 13, no. 8: 782-789.
External links
- Mitogen-Activated Protein Kinase Kinases at the US National Library of Medicine Medical Subject Headings (MeSH)
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
